News ArticleSterlite Technologies to Host Physical Plant Visit for Institutional Investors on November 13, 2026
Event organized by Nuvama Wealth Management Ltd at Chhatrapati Sambhajinagar plants during business hours
Sterlite Technologies has announced a scheduled plant visit for analysts and institutional investors organized by Nuvama Wealth Management Ltd on November 13, 2026, at its Chhatrapati Sambhajinagar plants. The visit will be conducted physically during business hours and no unpublished price-sensitive information will be shared.
Sterlite Technologies Limited
Investor Presentation
Sterlite Technologies Limited announced it will be hosting a physical plant visit for institutional investors and analysts on November 13, 2026, organized by Nuvama Wealth Management Ltd at its Chhatrapati Sambhajinagar plants during business hours.
The event is arranged on a group basis and will provide analysts and institutional investors an opportunity to visit the company’s facilities in person.
The company stated that only information already available in the public domain will be shared during the visit, with no unpublished price-sensitive information disclosed.
The schedule is subject to change if there are any exigencies on the part of the organizers or Sterlite Technologies.
This initiative highlights Sterlite Technologies’ efforts to engage with the investor community through direct interaction and transparency.
Highlights
- Plant visit scheduled for November 13, 2026, during business hours.
- Event organized by Nuvama Wealth Management Ltd for institutional investors and analysts.
- Physical visit to Sterlite Technologies’ Chhatrapati Sambhajinagar plants.
- No unpublished price-sensitive information will be shared during the visit.
- Schedule may change due to organizer or company exigencies.
Key Data Snapshot
What happened
- Sterlite Technologies is hosting a plant visit event for analysts and institutional investors on November 13, 2026.
- The event is organized in collaboration with Nuvama Wealth Management Ltd and will take place during business hours.
- Participants will visit the company’s plants located in Chhatrapati Sambhajinagar physically.
Key details
- The meeting will be conducted on a group basis for institutional investors and analysts.
- Only public domain information will be shared, ensuring compliance with securities regulations.
- The scheduled visit may be subject to change based on circumstances affecting the organizers or the company.
Regulatory and governance context
- The disclosure complies with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Sterlite Technologies confirmed no unpublished price-sensitive information will be shared during the interaction.
Highlights
- Plant visit scheduled for November 13, 2026, during business hours.
- Event organized by Nuvama Wealth Management Ltd for institutional investors and analysts.
- Physical visit to Sterlite Technologies’ Chhatrapati Sambhajinagar plants.
- No unpublished price-sensitive information will be shared during the visit.
- Schedule may change due to organizer or company exigencies.
Disclosures
- Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Investor Presentation
View allLatest corporate announcements and market updates in Investor Presentation.
Multi Commodity Exchange of India Ltd Reports Nearly 100% Increase in Total Income for H1 FY27 with ₹1,603 Crore
Multi Commodity Exchange of India Ltd (MCX) reported total income of ₹1,603 crore for the half year ended September 30, 2026, nearly doubling the ₹807 crore recorded in the same period last year. Profit after tax reached ₹868 crore, showcasing substantial financial growth.
Read Full Story
GlaxoSmithKline India Achieves 21% Revenue Growth in Q2 FY27 with Innovation-Driven Portfolio Expansion
GlaxoSmithKline Pharmaceuticals Limited reported a 21% revenue increase to ₹1180 crore in Q2 FY27, driven by strong sales execution and a rising contribution from its innovation portfolio which grew to 7% of total sales. The company sustained market leadership with a 25% share in its representative market amid competitive industry growth.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 mn Revenue in Q2 FY27 with 29% YoY Growth Bolstered by India Formulations
Zydus Lifesciences Limited recorded a 29% year-on-year increase in revenues to Rs. 79,096 million during the second quarter of fiscal year 2027, driven primarily by robust growth in their India branded formulations and North America markets.
Read Full Story
